Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials.
Hebert AA, Flohr C, Hong HC, Irvine AD, Pierce E, Elmaraghy H, Pillai S, Dawson Z, Chen S, Armengol C, Siegfried E, Weidinger S. Hebert AA, et al. Among authors: hong hc. J Dermatolog Treat. 2024 Dec;35(1):2324833. doi: 10.1080/09546634.2024.2324833. Epub 2024 May 12. J Dermatolog Treat. 2024. PMID: 38735650 Free article. Clinical Trial.
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis.
Simpson EL, de Bruin-Weller M, Hong HC, Staumont-Sallé D, Blauvelt A, Eyerich K, Gooderham M, Shahriari M, Mallbris L, Atwater AR, Rueda MJ, Ding Y, Liu Z, Agell H, Silverberg JI. Simpson EL, et al. Among authors: hong hc. Dermatol Ther (Heidelb). 2024 May;14(5):1145-1160. doi: 10.1007/s13555-024-01158-4. Epub 2024 May 3. Dermatol Ther (Heidelb). 2024. PMID: 38700646
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
Stein Gold L, Adam DN, Albrecht L, Alonso-Llamazares J, Ferris LK, Gooderham MJ, Hong HC, Kempers SE, Kircik LH, Lebwohl M, Loo WJ, Nahm WK, Papp KA, Stewart D, Toth DP, Zirwas M, Krupa D, Snyder S, Burnett P, Higham R, Berk DR. Stein Gold L, et al. Among authors: hong hc. J Am Acad Dermatol. 2024 Mar 29:S0190-9622(24)00541-3. doi: 10.1016/j.jaad.2024.03.030. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38556093 Free article.
Current Practices of Allergy Testing in Adults With Atopic Dermatitis in Canada: A National Survey.
Lee EY, Turchin I, Chan AW, Beecker J, Bissonnette R, Catherall H, Cresswell-Melville A, Gooderham M, Hawkins N, Hong HC, Levell NJ, Lapointe McKenzie JA, Manion R, Papp K, Drucker AM. Lee EY, et al. Among authors: hong hc. J Cutan Med Surg. 2024 Mar 19:12034754241239260. doi: 10.1177/12034754241239260. Online ahead of print. J Cutan Med Surg. 2024. PMID: 38504147 No abstract available.
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).
Gooderham M, Vender R, Crowley J, Hong HC, Feely M, Garrelts A, See K, Konicek B, Green L. Gooderham M, et al. Among authors: hong hc. Dermatol Ther (Heidelb). 2024 Feb;14(2):441-451. doi: 10.1007/s13555-023-01075-y. Epub 2024 Feb 9. Dermatol Ther (Heidelb). 2024. PMID: 38332436 Free PMC article.
158 results